CTAS

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, mai 8, 2024
LDLR, Verve, Safety, Pharmacokinetics, ASCVD, LNP, Eli Lilly, Moyamoya disease, N-Acetylgalactosamine, RNA, Aortic stenosis, Stroke, Cell, Conference, Research, Webcast, PCSK9, IND, Administration, Potential, Research and development, Patient, Liver, Gene, CAD, Society, Medicine, ANGPTL3, Lilly, Cardiovascular disease, CTAS, Therapy, Asialoglycoprotein receptor, G&A, LPA, Pharmaceutical industry

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the quarter ended March 31, 2024.

Key Points: 
  • Cash Position: Verve ended the first quarter of 2024 with $606.4 million in cash, cash equivalents, and marketable securities.
  • Collaboration Revenue: Collaboration revenue was $5.7 million for the first quarter of 2024, compared to $1.4 million for the first quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $14.2 million for the first quarter of 2024, compared to $12.6 million for the first quarter of 2023.
  • Stock-based compensation expense included in G&A expenses was $4.7 million and $3.5 million for the first quarter of 2024 and 2023, respectively.

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
Mardi, mai 7, 2024
Neuromuscular disease, CTN, DMD, Research, Administration, IND, Research and development, Patient, EEV, Duchenne muscular dystrophy, DM1, Clinical trial, CTAS, Therapy, G&A, Pharmaceutical industry

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company today reported financial results for the first quarter ended March 31, 2024, and highlighted recent business updates.

Key Points: 
  • The Company today reported financial results for the first quarter ended March 31, 2024, and highlighted recent business updates.
  • “The first quarter of 2024 was a period of significant clinical progress for Entrada.
  • Entrada expects to report data from the clinical trial in October of 2024.
  • The increase was primarily a result of the clinical advancement milestone achieved in the first quarter of 2024.

Cintas Board of Directors Approves 4-For-1 Stock Split

Retrieved on: 
Jeudi, mai 2, 2024
Construction & Property, Office Products, Other Retail, Textiles, Building Systems, Specialty, Manufacturing, Retail, CTAS, Cintas, Corporation, Growth

Cintas Corporation (Nasdaq: CTAS), a leading provider of business-to-business services, today announced that its Board of Directors approved a four-for-one split of its common stock.

Key Points: 
  • Cintas Corporation (Nasdaq: CTAS), a leading provider of business-to-business services, today announced that its Board of Directors approved a four-for-one split of its common stock.
  • Cintas’ shares are expected to begin trading on a post-split basis at the market open on Thursday, September 12, 2024.
  • Prior to this announcement, Cintas’ most recent stock split was in 2000.
  • “Cintas shares are trading near record highs as a result of our steadfast focus on serving our customers.

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Retrieved on: 
Jeudi, avril 25, 2024
CTA, Synovial sarcoma, Safety, Cytokine, MD, Stomach, DP, Interferon, PD-L1, CHI, Patient, Neoplasm, CSP, DPS, CTAS, TCR, Ovarian cancer, Vaccine

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.

Key Points: 
  • Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.
  • This process is vital for producing effective, safe, and durable TCR-T therapies," stated Kirsty Crame, MD, VP Clinical Strategy & Development.
  • Medigene has developed a streamlined 6-day manufacturing process that focuses on the enrichment of CD8+ T cells whilst simultaneously maintaining a high degree of stemness.
  • Clinical indications for MDG1015 were primarily chosen based on the high unmet medical need, expression of the target antigen and/or PD-L1.

Minnesota Custodian Cleans Up the 2024 Cintas Custodian of the Year Contest

Retrieved on: 
Mardi, avril 30, 2024
Professional Services, Office Products, Other Construction & Property, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Primary, Secondary, Education, Retail, Other Professional Services, Building Systems, Human Resources, Manufacturing, Rubbermaid Commercial Products, Partnership, Student, CTAS, Senior, SVP, Family, ISSA, Multimedia, Global Biorisk Advisory Council, Management

Congratulations to the 11th annual Cintas Custodian of the Year contest winner, Bob Galewski, from Wabasha-Kellogg High School in Wabasha, Minnesota!

Key Points: 
  • Congratulations to the 11th annual Cintas Custodian of the Year contest winner, Bob Galewski, from Wabasha-Kellogg High School in Wabasha, Minnesota!
  • After thousands of votes were submitted, Cintas Corporation (Nasdaq: CTAS) confirmed Bob Galewski is this year’s grand prize winner.
  • View the full release here: https://www.businesswire.com/news/home/20240430742176/en/
    Congratulations to the 11th annual Cintas Custodian of the Year contest winner, Bob Galewski, from Wabasha-Kellogg High School in Wabasha, Minnesota!
  • For more information about the Cintas Custodian of the Year contest, visit custodianoftheyear.com .

Forbes Recognizes Cintas as One of the Best Employers for Diversity 2024

Retrieved on: 
Lundi, avril 29, 2024
Other Retail, Professional Services, LGBTQ+, Office Products, Consumer, Construction & Property, DEI (Diversity, Equity and Inclusion), Textiles, Retail, Human Resources, Building Systems, Manufacturing, Corporation, Human resources, Disability, Workplace, Research, Accountability, CTAS, Newsweek, Communication, Culture, Representation, Multimedia, Cintas, Nursing

Cintas Corporation (Nasdaq: CTAS) has been recognized on the Forbes list of the Best Employers for Diversity 2024 for its efforts in creating a diverse and inclusive workplace.

Key Points: 
  • Cintas Corporation (Nasdaq: CTAS) has been recognized on the Forbes list of the Best Employers for Diversity 2024 for its efforts in creating a diverse and inclusive workplace.
  • View the full release here: https://www.businesswire.com/news/home/20240429302691/en/
    Cintas has been recognized on the Forbes list of the Best Employers for Diversity 2024 for its efforts in creating a diverse and inclusive workplace.
  • (Photo: Business Wire)
    “Diversity is a crucial part of our culture and success here at Cintas,” said Todd Schneider, Cintas President and CEO.
  • This is the second time this year that Cintas has been recognized for being one of the best employers for diversity in the U.S. Cintas was also recognized as one of America’s Greatest Workplaces for Diversity by Newsweek earlier this year.

New ON24 Report Reveals Significant Increase in Engagement as Digital Transformation Accelerates in the Financial Services Industry

Retrieved on: 
Mardi, avril 16, 2024
Software, Technology, Artificial Intelligence, Data Management, CTA, Marketing, Yoy, CMO, CTAS, B2B, Research, ON24, AI

Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B sales and marketing, announced the release of its “2024 Financial Services Digital Engagement Benchmarks Report.” The comprehensive analysis unveils key digital engagement trends within the financial services sector, providing insights for marketers aiming to increase engagement with clients, agents and advisors, build thought leadership, generate demand and ultimately increase business results.

Key Points: 
  • Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B sales and marketing, announced the release of its “2024 Financial Services Digital Engagement Benchmarks Report.” The comprehensive analysis unveils key digital engagement trends within the financial services sector, providing insights for marketers aiming to increase engagement with clients, agents and advisors, build thought leadership, generate demand and ultimately increase business results.
  • After analyzing interactions from thousands of financial services webinars and content experiences in 2023, the report reveals shifts in audience behavior and concludes that personalization is the biggest factor for driving business growth in the industry.
  • Financial services companies have seen an 18% increase in calls-to-action (CTA) engagement since 2022 and more than double the growth rate within personalized CTAs.
  • This trend is indicative of clients, agents and advisors’ increasing preference for online channels, highlighting the importance of a digital-first engagement strategy.

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Retrieved on: 
Mardi, avril 16, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, CTA, CRISPR, PMM, OTC, Gene editing, Partnership, Doctor of Philosophy, DMD, Prevail, Webcast, IND, Entrepreneurship, Novartis, DNA, Precision BioSciences, GLP, Eli Lilly and Company, CTAS, Toxicology, ID, Therapy, Precision, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
  • Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.
  • The collaboration began in January 2021 and was amended in June 2023 to transfer certain preclinical research, manufacturing, and investigational new drug (IND)-enabling activities from Precision BioSciences to Prevail Therapeutics.
  • “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs.

Verve Therapeutics Announces Updates on its PCSK9 Program

Retrieved on: 
Mardi, avril 2, 2024
LDLR, Cardiovascular disease, Gene editing, PCSK9, ALT, Patient, RNA, Health care, Health Canada, IND, N-Acetylgalactosamine, MHRA, Asialoglycoprotein receptor, Clinical trial, CTAS, Therapy, Bleeding, Safety, Moyamoya disease, DSMB, FDA, Liver, ASCVD, LNP, Medsafe, Hypercholesterolemia, Food, Pharmaceutical industry

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced updates from the Heart-1 Phase 1b clinical trial of VERVE-101 and clearance of its Clinical Trial Applications (CTAs) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada for VERVE-102, with the Heart-2 Phase 1b clinical trial expected to initiate in the second quarter of this year.

Key Points: 
  • Six participants have been dosed at 0.45 mg/kg of VERVE-101, with a total of 13 participants dosed in the study.
  • Verve is conducting an investigation into the laboratory abnormalities and based on those results, expects to work with regulatory authorities to define a path forward for VERVE-101.
  • Verve is now prioritizing the development of VERVE-102 and the initiation of the Heart-2 clinical trial.
  • VERVE-102 uses the same base editor and guide RNA for PCSK9 but a different lipid nanoparticle (LNP) delivery system than VERVE-101.

Cintas Corporation Announces Quarterly Cash Dividend

Retrieved on: 
Mardi, avril 9, 2024
Retail, Manufacturing, Specialty, Construction & Property, Building Systems, Textiles, CTAS, Corporation, Standard, Fortune 500, Holding company

Cintas Corporation (Nasdaq: CTAS) announced that the Company’s Board of Directors approved a quarterly cash dividend of $1.35 per share of common stock payable on June 14, 2024, to shareholders of record at the close of business on May 15, 2024.

Key Points: 
  • Cintas Corporation (Nasdaq: CTAS) announced that the Company’s Board of Directors approved a quarterly cash dividend of $1.35 per share of common stock payable on June 14, 2024, to shareholders of record at the close of business on May 15, 2024.
  • Cintas has a strong record of returning capital to its shareholders and has consistently raised its dividend each year since Cintas’ initial public offering 41 years ago in 1983.
  • Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customers’ facilities and employees clean, safe, and looking their best.
  • With offerings including uniforms, mats, mops, towels, restroom supplies, workplace water services, first aid and safety products, eye-wash stations, safety training, fire extinguishers, sprinkler systems and alarm service, Cintas helps customers get Ready for the Workday®.